AstraZeneca: no time for time-wasting

Scott Alban, who is charged with protecting the innovation arising from AstraZeneca and its global biologics research and development (R&D) arm, MedImmune, spoke to LSIPR about protecting innovation, obtaining adequate protection and licensing at AstraZeneca, which invests approximately 25% of its revenue back into R&D annually.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Attorney v examiner: Navigating patenting's AI tools ‘arms race’

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

USPTO clarifies AI's role in patent eligibility

AstraZeneca: no time for time-wasting

Editor's picks

Editor's picks

More features